Exagen (XGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
The annual meeting is scheduled for June 9, 2026, with voting on director elections, auditor ratification, and executive compensation advisory approval.
Shareholders can vote online, by phone, mail, or in person, with detailed instructions provided for each method.
Proxy materials are primarily distributed electronically to reduce costs and environmental impact.
Voting matters and shareholder proposals
Shareholders will vote to elect two Class I directors for three-year terms, ratify BDO USA, P.C. as auditor for 2026, and approve executive compensation on an advisory basis.
Board recommends voting FOR all proposals.
Shareholders may submit proposals for the 2027 meeting by December 28, 2026, and must follow specific advance notice and content requirements.
Board of directors and corporate governance
Board consists of seven members, with a majority deemed independent under Nasdaq rules.
Board is divided into three classes with staggered terms; directors may only be removed for cause by a two-thirds vote.
Executive Chairman and CEO roles are separated for balanced governance.
Committees include Audit, Compensation, and Nominating, each with defined charters and independent members.
Annual board and committee evaluations are conducted.
Latest events from Exagen
- Director elections, auditor ratification, and executive pay are up for vote at the 2026 meeting.XGN
Proxy filing27 Apr 2026 - 2025 revenue rose 20% to $66.6M, with improved margins and strong AVISE CTD test growth.XGN
Q4 202510 Mar 2026 - Record Q2 revenue, margin gains, and raised outlook signal progress toward profitability.XGN
Q2 20242 Feb 2026 - Record revenue, margin gains, and new test enhancements set up cash flow positivity by 2025.XGN
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Q3 2024 saw higher ASP, narrowed losses, and new biomarkers set up for 2025 profitability.XGN
Q3 202414 Jan 2026 - Turnaround delivers ASP growth, new products, and a path to cash flow positivity in 2024.XGN
TD Cowen 45th Annual Healthcare Conference30 Dec 2025 - Record revenue, margin expansion, and new biomarkers set up for profitable growth in 2025.XGN
Q4 202426 Dec 2025 - Registering 1,150,000 shares for resale linked to a $75M term loan and warrant agreement.XGN
Registration Filing16 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and executive pay, with board support for all.XGN
Proxy Filing2 Dec 2025